[{"id":"3620a279-00d9-40e2-8835-c205c51f9360","acronym":"","url":"https://clinicaltrials.gov/study/NCT03792633","created_at":"2021-01-18T18:45:04.269Z","updated_at":"2025-02-25T16:59:53.561Z","phase":"Phase 2","brief_title":"Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL","source_id_and_acronym":"NCT03792633","lead_sponsor":"University of Pennsylvania","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huCART19"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 04/04/2024","primary_completion_date":" 04/04/2024","study_txt":" Completion: 04/04/2024","study_completion_date":" 04/04/2024","last_update_posted":"2025-02-03"},{"id":"ee6449ac-5095-4fbb-b724-e910caded562","acronym":"","url":"https://clinicaltrials.gov/study/NCT03620058","created_at":"2021-01-18T17:47:19.570Z","updated_at":"2024-07-02T16:35:00.949Z","phase":"Phase 1","brief_title":"CART22 Alone or in Combination With huCART19 for ALL","source_id_and_acronym":"NCT03620058","lead_sponsor":"University of Pennsylvania","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CART22 • huCART19"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 09/27/2018","start_date":" 09/27/2018","primary_txt":" Primary completion: 01/01/2036","primary_completion_date":" 01/01/2036","study_txt":" Completion: 01/01/2036","study_completion_date":" 01/01/2036","last_update_posted":"2024-05-24"},{"id":"363e96eb-5e3f-442c-b58a-38eaeb74e6d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684563","created_at":"2021-03-16T19:53:11.570Z","updated_at":"2024-07-02T16:35:04.117Z","phase":"Phase 1","brief_title":"huCART19-IL18 in NHL/CLL Patients","source_id_and_acronym":"NCT04684563","lead_sponsor":"University of Pennsylvania","biomarkers":" ALK • BCL2 • CD19 • BCL6","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huCART19 • huCART19-IL18"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/06/2021","start_date":" 05/06/2021","primary_txt":" Primary completion: 05/01/2036","primary_completion_date":" 05/01/2036","study_txt":" Completion: 05/01/2036","study_completion_date":" 05/01/2036","last_update_posted":"2024-05-13"},{"id":"70500982-fdb6-4f26-bc62-15198d012f0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05674175","created_at":"2023-01-06T15:58:48.048Z","updated_at":"2024-07-02T16:35:25.792Z","phase":"Phase 1/2","brief_title":"Co-administration of CART22-65s and huCART19 for B-ALL","source_id_and_acronym":"NCT05674175","lead_sponsor":"Stephan Grupp MD PhD","biomarkers":" CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • CART22 • huCART19"],"overall_status":"Recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 01/15/2029","study_completion_date":" 01/15/2029","last_update_posted":"2023-12-19"},{"id":"d739dec3-fc20-4ef9-8305-ff27b6ac5f7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05480449","created_at":"2022-07-29T15:55:22.901Z","updated_at":"2024-07-02T16:35:25.747Z","phase":"Phase 1/2","brief_title":"Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)","source_id_and_acronym":"NCT05480449","lead_sponsor":"Stephan Grupp MD PhD","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huCART19"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 09/20/2027","primary_completion_date":" 09/20/2027","study_txt":" Completion: 09/20/2029","study_completion_date":" 09/20/2029","last_update_posted":"2023-12-19"},{"id":"1f23e52c-ada2-4aed-851f-4195569243d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02374333","created_at":"2021-01-18T11:18:33.644Z","updated_at":"2024-07-02T16:36:24.086Z","phase":"Phase 1","brief_title":"Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy","source_id_and_acronym":"NCT02374333","lead_sponsor":"University of Pennsylvania","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huCART19"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 03/25/2014","start_date":" 03/25/2014","primary_txt":" Primary completion: 09/02/2021","primary_completion_date":" 09/02/2021","study_txt":" Completion: 09/02/2021","study_completion_date":" 09/02/2021","last_update_posted":"2021-09-23"}]